Biotech pipeline hosts 163 potential meds for mental illness, with depression dominating: PhRMA

Medicines designed to treat psychiatric conditions may have a statistically lower chance of succeeding in drug development than most other disease areas, but that doesn't seem to put off biopharmas. In fact, there are at least 163 medicines targeting mental illness already in the clinic or awaiting FDA review, according to a report from the Pharmaceutical Research and Manufacturers of America (PhRMA).